79 related articles for article (PubMed ID: 16514616)
21. Role of 18F-FDG-PET/CT in the management of Burkitt lymphoma.
Carrillo-Cruz E; Marín-Oyaga VA; Solé Rodríguez M; Borrego-Dorado I; de la Cruz Vicente F; Quiroga Cantero E; Manzanares Pérez M; Capote FJ; Ramírez Sánchez MJ; Espigado Tocino I; Pérez-Vega H; Vázquez-Albertino R; Pérez-Simón JA
Eur J Haematol; 2015 Jan; 94(1):23-30. PubMed ID: 24520874
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
Kostakoglu L; Goldsmith SJ; Leonard JP; Christos P; Furman RR; Atasever T; Chandramouly A; Verma S; Kothari P; Coleman M
Cancer; 2006 Dec; 107(11):2678-87. PubMed ID: 17063502
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of 18F-FDG coincidence SPECT imaging and computed tomography in the initial staging and therapeutic evaluation of lymphomas].
Qiao WL; Zhao JH; Wang C; He ZY; Wang TS; Xing Y
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):536-9. PubMed ID: 18069637
[TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
25. The clinical utility of PET/CT scan and tissue biopsy in the management and follow-up of paediatric Hodgkin lymphoma in South Africa.
Heyman K; Hyman G; Kolia R; Nicholaides K; Govender V; McMaster J; Harrison D
S Afr J Surg; 2023 Sep; 61(3):28-34. PubMed ID: 37791711
[TBL] [Abstract][Full Text] [Related]
26. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
[TBL] [Abstract][Full Text] [Related]
27. SUV-measurements and patient-specific corrections in pediatric Hodgkin-lymphoma: is there a benefit for PPV in early response assessment by FDG-PET?
Furth C; Meseck RM; Steffen IG; Schoenberger S; Denecke T; Henze G; Hautzel H; Hofheinz F; Großer O; Hundsdoerfer P; Amthauer H; Ruf J
Pediatr Blood Cancer; 2012 Sep; 59(3):475-80. PubMed ID: 22190514
[TBL] [Abstract][Full Text] [Related]
28. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
Pelosi E; Penna D; Deandreis D; Chiappella A; Skanjeti A; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
[TBL] [Abstract][Full Text] [Related]
29. Pediatric Hodgkin lymphoma: are we over-scanning our patients?
Rathore N; Eissa HM; Margolin JF; Liu H; Wu MF; Horton T; Kamdar K; Dreyer Z; Steuber P; Rabin KR; Redell M; Allen CE; McClain KL; Guillerman RP; Bollard CM
Pediatr Hematol Oncol; 2012 Aug; 29(5):415-23. PubMed ID: 22632168
[TBL] [Abstract][Full Text] [Related]
30. Pediatric Hodgkin Lymphoma: CT features at presentation, on treatment and its prognostic significance.
Dinesh K; Thulkar S; Bakhshi S; Madhusudan KS; Upadhyay AD
Indian J Pediatr; 2011 May; 78(5):549-54. PubMed ID: 21203865
[TBL] [Abstract][Full Text] [Related]
31. An evaluation of the predictive value of mid-treatment 18F-FDG-PET/CT scans in pediatric lymphomas and undefined criteria of abnormality in quantitative analysis.
Zhu HJ; Halkar R; Alavi A; Goris ML
Hell J Nucl Med; 2013; 16(3):169-74. PubMed ID: 24137579
[TBL] [Abstract][Full Text] [Related]
32. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
34. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Goldschmidt N; Or O; Klein M; Savitsky B; Paltiel O
Ann Hematol; 2011 Feb; 90(2):165-71. PubMed ID: 20706721
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.
Bjurberg M; Gustavsson A; Ohlsson T; Brun E
Acta Oncol; 2006; 45(6):743-9. PubMed ID: 16938818
[TBL] [Abstract][Full Text] [Related]
36. Negative gallium-67 citrate and positive positron emission tomography/computed tomography spleen scans, in Hodgkin's stage IV lymphoma.
Malamitsi J; Kosmidis H; Valotassiou B; Bonou I; Andreou J
Hell J Nucl Med; 2007; 10(2):116-8. PubMed ID: 17684589
[TBL] [Abstract][Full Text] [Related]
37. The impact of FDG positron emission tomography imaging on the management of lymphomas.
Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL
Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743
[TBL] [Abstract][Full Text] [Related]
38. Predictive role of positron emission tomography in the outcome of patients with follicular lymphoma.
Zinzani PL; Musuraca G; Alinari L; Fanti S; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Castellucci P; Farsad M; Baccarani M
Clin Lymphoma Myeloma; 2007 Jan; 7(4):291-5. PubMed ID: 17324337
[TBL] [Abstract][Full Text] [Related]
39. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate.
Levine JM; Weiner M; Kelly KM
J Pediatr Hematol Oncol; 2007 Sep; 29(9):667. PubMed ID: 17805052
[No Abstract] [Full Text] [Related]
40. Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
Kluge R; Wittig T; Georgi TW; Kurch L; Sabri O; Wallace WH; Klekawka T; Fernández-Teijeiro A; Ceppi F; Karlén J; Pears J; Cepelová M; Fosså A; Beishuizen A; Hjalgrim LL; Körholz D; Mauz-Körholz C; Hasenclever D
J Nucl Med; 2021 Mar; 62(3):338-341. PubMed ID: 32764122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
